SEMBER MICHAEL T 4

What Happened
Michael T. Sember, a director of Quoin Pharmaceuticals (QNRX), was granted a derivative award reported as 8,141 ADS-equivalent units on Feb 4, 2026. The filing lists an acquisition price of $0.00 (no cash paid at grant). Because the award is reported in ADSs, it represents approximately 284,935 ordinary shares (1 ADS = 35 ordinary shares).

Key Details

• Transaction date: 2026-02-04; Form 4 filed 2026-02-06 (timely filing).
• Transaction type/code: Award/Grant (A). Acquisition price listed as $0.00.
• Quantity: 8,141 ADS-equivalent units = 284,935 ordinary shares (8,141 × 35).
• Vesting: vests in four installments — 20% each on Feb 4 of 2027, 2028 and 2029, and 40% on Feb 4, 2030. (Footnotes F1 & F2).
• Shares owned after transaction: Not reported on this filing.
• No indication of a 10b5-1 plan, tax withholding, or immediate sale in the filing.

Context
This is an award/grant (an acquisition of derivative securities) rather than an open-market buy or sale. The $0.00 acquisition price indicates no cash paid at grant; such awards commonly vest over time and do not necessarily reflect immediate buying or selling of stock. For retail investors, awards can signal alignment of insider compensation with future company performance, but they are not the same as an insider purchasing shares outright.